viewVerona Pharma

Ensifentrine offers real benefit to COPD sufferers believes Verona Pharma PLC CEO Karlsson

Verona Pharma PLC (LON:VRP) has a huge twelve months ahead for its COPD treatment ensifentrine, chief executive Jan-Anders Karlsson tells Proactive. 

Recent phase II trial data indicated that a new dry powder formulation significantly improved the breathing and the lung condition of less severe sufferers of the often fatal disease. 

Karlsson says the data 'really demonstrates' that the new dry powder formulation works and offers something new to the huge market for pocket inhalers for less severe COPD sufferers.  

More work needs to be done to refine the dry powder variation including larger and longer trials than seen thus far and Verona is looking for a partner. 

In the meantime, Verona is working towards a phase III trial of a nebuliser formulation of ensifentrine for very severe COPD patients.

Karlsson says this will be its first product to market and he is very upbeat over the possibilities. 

“Ensifentrine offers something different for COPD sufferers.”

Quick facts: Verona Pharma

Price: 48 GBX

Market: AIM
Market Cap: £50.56 m


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Verona Pharma named herein, including the promotion by the Company of Verona Pharma in any Content on the Site, the Company receives from said...



Verona Pharma can make real difference to COPD market believes CEO Karlsson

Jan-Anders Karlsson says the recent strengthening of its management team has given Verona Pharma  PLC (LON:VRP) the experience to take its respiratory disease treatment Ensifentrine to market. The COPD drug is undergoing a phase IIb trial with 400 very severe sufferers who use a...

on 8/7/19

2 min read